adjuvant therapies - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	secondary prevention
adjuvant therapies
anticoagulant
rivaroxaban	MICHELLE

18 studies excluded by filtering options 3

5156	Teleman, 2004	2	20	0	excluded	not a RCT	risk of bias not avaialble
5157	Wu, 2004	2	20	0	excluded	not a RCT	risk of bias not avaialble
5158	Loeb, 2004	2	20	0	excluded	not a RCT	risk of bias not avaialble
5159	Wilder-Smith, 2005	2	20	0	excluded	not a RCT	risk of bias not avaialble
5160	Wang, 2020	2	20	0	excluded	not a RCT	risk of bias not avaialble
5162	Cheng, 2010	2	20	0	excluded	not a RCT	risk of bias not avaialble
5164	Jaeger, 2011	2	19	0	excluded	not a RCT	risk of bias not avaialble
5167	Chokephaibulkit, 2012	2	20	0	excluded	not a RCT	risk of bias not avaialble
5168	Zhang, 2012	2	20	0	excluded	not a RCT	risk of bias not avaialble
5169	Sung, 2016	2	13	0	excluded	not a RCT	risk of bias not avaialble
5170	Zhang, 2017	2	20	0	excluded	not a RCT	risk of bias not avaialble
5172	Ma, 2004	2	20	0	excluded	not a RCT	risk of bias not avaialble
5173	Yin, 2004	2	20	0	excluded	not a RCT	risk of bias not avaialble
5176	Zhang, 2013	2	13	0	excluded	not a RCT	risk of bias not avaialble
5177	Nishiura, 2005	2	20	0	excluded	not a RCT	risk of bias not avaialble
5355	Paranjpe, 2020	1	13	4		not a RCT	high risk of bias
5441	Ayerbe, 2020	1	13	0		not a RCT	risk of bias not avaialble
6283	Lynn, 2020	0	13	0	selection pending